Table 1 Baseline data of HD individuals and healthy controls
From: Increase of angiotensin II type 1 receptor auto-antibodies in Huntington’s disease
Parameter | HD individuals | Healthy controls |
|---|---|---|
(n = 132) | (n = 129) | |
Age [yr] | 46.9 ± 12.8 | 47.5 ± 9.8 |
(21–89) | (22–56) | |
Weight [kg] | 68.4 ± 14.3 | 73.4 ± 14 |
(40–101) | (50–115, n = 103) | |
Height | 171.7 ± 9.1 | 170 ± 9.7 |
(157–197) | (150–191, n = 103) | |
Smoking [%] | 34.8 | 34.4 (n = 125) |
CAG expanded | 44.7 ± 4.7 | ----- |
(39–70) | ||
Disease burden score | 403.9 ± 133.6 | ----- |
(91–825) | ||
Onset motor [yr] | 41.5 ± 12.1 | ----- |
(10–72, n = 102) | ||
Onset psychiatric [yr] | 42.2 ± 12.1 | ----- |
(15–73, n = 57) | ||
Duration of disease [yr] | 7.6 ± 5.1 | ----- |
(0.1-23, n = 102) | ||
YTO Langbehn [yr] | 16.9 ± 9.1 | ----- |
(5–43, n = 30) | ||
UHDRS MS | 41.9 ± 29.7 | ----- |
(0–96) | ||
UHDRS TFC | 7.6 ± 4.5 | ----- |
(0–13) | ||
UHDRS IS | 70.5 ± 26.5 | ----- |
(10–100) | ||
UHDRS CS | 159.5 ± 108.8 | ----- |
(0–379) | ||
Tapping dominant | 162 ± 43.7 | ----- |
(65–233, n = 55) | ||
Tapping non-dominant | 139.1 ± 46.9 | ----- |
(40–207, n = 55) | ||
Peg board dominant [sec] | 52.6 ± 13.6 | ----- |
(32.5-88.5, n = 55) | ||
Peg board non-dominant [sec] | 58.6 ± 16.0 | ----- |
(38.7-100, n = 55) |